| P50 | author | Pantelis A Sarafidis | Q89821637 |
| P2093 | author name string | George L Bakris | |
| | Panagiotis I Georgianos | |
| P2860 | cites work | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | Q24657470 |
| | Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 |
| | Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? | Q28273680 |
| | Hyperkalemia and hyporeninemic hypoaldosteronism | Q28276420 |
| | Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 |
| | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 |
| | Trimethoprim-induced hyperkalemia: An analysis of reported cases | Q33679685 |
| | ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group | Q33922528 |
| | Drug-induced hyperkalemia: old culprits and new offenders | Q34038717 |
| | Regulation of potassium channel trafficking in the distal nephron | Q34117186 |
| | Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study | Q34281438 |
| | Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. | Q34448201 |
| | Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors | Q34448983 |
| | Sodium zirconium cyclosilicate in hyperkalemia | Q34448992 |
| | Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial | Q34751971 |
| | Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone | Q35141436 |
| | Aldosterone in the development and progression of renal injury | Q35807297 |
| | Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system | Q35856246 |
| | Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. | Q36126918 |
| | Metabolic complications in elderly adults with chronic kidney disease. | Q36479806 |
| | The frequency of hyperkalemia and its significance in chronic kidney disease. | Q36530203 |
| | Antihypertensive therapy in the presence of proteinuria | Q36690664 |
| | Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol | Q36802493 |
| | Timing of onset of CKD-related metabolic complications | Q37042178 |
| | Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review | Q37063760 |
| | Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors | Q37691122 |
| | Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers | Q37925006 |
| | Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms | Q37984206 |
| | Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. | Q38017494 |
| | Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice | Q38040078 |
| | Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy | Q38052452 |
| | Thiazide diuretics as chronic antihypertensive therapy in patients with severe renal disease--is there a role in the absence of diuresis? | Q38058500 |
| | Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review | Q38074251 |
| | Regulation of renal potassium secretion: molecular mechanisms | Q38129579 |
| | Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? | Q38139240 |
| | Prediction and management of hyperkalemia across the spectrum of chronic kidney disease | Q38228688 |
| | Management of hyperkalaemia in chronic kidney disease | Q38249892 |
| | Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial | Q38408065 |
| | Heparin-induced aldosterone suppression and hyperkalemia | Q38572760 |
| | eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population | Q43264358 |
| | Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy | Q43270031 |
| | Predictors of hyperkalemia risk following hypertension control with aldosterone blockade | Q43279459 |
| | Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia | Q43498899 |
| | Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease | Q43743641 |
| | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial | Q44218873 |
| | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 |
| | Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Telmisartan, ramipril, or both in patients at high risk of vascular events | Q46462657 |
| | Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study | Q46670272 |
| | Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study | Q48351927 |
| | Predictors of hyperkalemia and death in patients with cardiac and renal disease | Q48728677 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2205-2215 | |
| P577 | publication date | 2015-09-02 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Advances in treatment of hyperkalemia in chronic kidney disease | |
| P478 | volume | 16 | |